Business Wire

VeriSilicon Partners With LVGL to Enable Advanced GPU Acceleration for Wearable Devices and Beyond

29.11.2024 01:00:00 CET | Business Wire | Press release

Share

LVGL adds VeriSilicon’s 3D and VGLite 2.5D GPUs support to its library for a wide range of embedded applications

VeriSilicon (688521.SH) today announced a strategic partnership with LVGL, the leading open-source graphics library for embedded systems, to support VeriSilicon’s low-power 3D and VGLite 2.5D GPU technology within the LVGL library. This partnership aims to optimize performance and expand graphic processing capabilities for a wide range of embedded applications. As one of the first providers of 3D GPU technology for the LVGL ecosystem, VeriSilicon will contribute to advancing 3D rendering capabilities within the LVGL library.

LVGL is the most popular free and open-source embedded graphics library to create beautiful User Interfaces (UIs) for any Microcontroller Units (MCUs), Micro Processor Units (MPUs), or display type. By integrating VeriSilicon’s low-power and high-performance GPU solutions into LVGL’s graphics ecosystem, it offers developers the ability to rapidly deliver improved visual experiences, while maintaining power efficiency on compact, resource-constrained devices.

Actions Technology, a low-power AIoT fabless semiconductor company, is among the first to adopt this integrated solution in their smart watch System-on-Chips (SoCs). The company recognizes the potential of VeriSilicon’s low-power GPU technology, which, in conjunction with LVGL’s graphics library, will enhance the user experience of next-generation wearable devices.

Gabor Kiss-Vamosi, CEO of LVGL, said, “VeriSilicon’s VGLite 2.5D GPU technology has pioneered a new era in the embedded world, enabling complex vector graphics with exceptional speed and low power consumption. Now, we stand at the edge of a new revolution: the arrival of 3D GPUs to MCUs. This breakthrough will transform the embedded UI landscape, unlocking never-before-seen possibilities for user interfaces on small, resource-constrained, and battery-powered devices. At LVGL, we are excited to embrace this technology and harness its potential across a wide range of platforms. Our goal is to provide a great developer experience for VeriSilicon’s 3D GPUs, enabling seamless integration of 2D, 2.5D, and 3D content that will no doubt lead to some remarkable embedded applications.”

Tim Zhang, Wearable and Sensing Business Unit General Manager of Actions Technology, said, “LVGL’s flexible and powerful graphics solutions are essential to enhance the user interfaces of our wearable products. As the wearable industry embraces 3D graphics, the adoption of VeriSilicon’s powerful and energy-efficient technologies enables us to push the boundaries of innovation, delivering rich 3D graphics with low power consumption.”

“Wearable products are experiencing rapid growth, offering extended functionalities that go far beyond traditional watches. They have evolved into accessible information devices with integrated health monitoring features,” said Weijin Dai, Executive Vice President and General Manager of VeriSilicon’s IP Division. “With this growth, delivering a powerful user interface to effectively communicate information on small displays, while maintaining low power consumption, has become essential. At VeriSilicon, we work closely with our customers to integrate 3D GPU technology into their next-generation products. As a leading provider of wearable GPUs for both 2.5D and 3D applications, we collaborate with LVGL and partners like Actions to drive innovation and achieve this mission.”

About LVGL

LVGL Kft. is the creator of LVGL, the leading free and open-source graphics library for embedded systems, enabling high-quality UIs on any Microcontroller Unit (MCU), Micro Processor Unit (MPU), or display type. With a global community and industry partnerships, LVGL empowers developers to build visually rich, responsive, and efficient UIs for resource-constrained devices from wearables to industrial equipment. For more information, visit www.lvgl.io.

About Actions Technology

Actions Technology (688049.SH) is a leading low-power AIoT fabless semiconductor company in China. We excel in providing high-quality and low-latency wireless audio experiences while prioritizing power efficiency. Our core expertise includes high-performance audio ADC/DAC, voice pre-processing, audio encoding/decoding, and audio post-processing technologies, enabling a superior audio signal chain. Additionally, we specialize in low-latency wireless connectivity with Bluetooth RF, baseband, and protocol stack technologies at the core. For more information about Actions® high-quality, low-latency platform, visit www.actionstech.com.

About VeriSilicon

VeriSilicon is committed to providing customers with platform-based, all-around, one-stop custom silicon services and semiconductor IP licensing services leveraging its in-house semiconductor IP. For more information, please visit: www.verisilicon.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20241128646659/en/

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Align Partners Issues Public Shareholder Letter and Submits Formal Shareholder Proposals to DB Insurance9.2.2026 15:26:00 CET | Press release

Align Partners underscores DBI’s persistent undervaluation (0.40x Adjusted PBR), despite industry-leading profitability, identifying inefficient capital allocation and governance issues as primary driversAlign Partners outlines measures for capital efficiency and governance normalization; requests a revised “Value-up” plan and a formal response from the Board by March 6, 2026The proposals nominate two Independent Directors via separate election and calls for the reinstatement of the Internal Transaction Committee Align Partners Capital Management Inc. (“Align Partners”), a shareholder of DB Insurance Co., Ltd. (KRX:005830) (“DBI” or the “Company”) holding 1.9%, has issued a public shareholder letter to DBI’s Board of Directors aimed at strengthening capital allocation policy and governance oversight, and submitted formal shareholder proposals for the 2026 Annual General Meeting (“AGM”). Despite DBI’s robust fundamentals—including a 16.1% ROE and a 226% K-ICS ratio—the Company trades at

Promega Unveils Cellular Target Engagement Technology Aimed at Expanding the Druggable Proteome at SLAS 20269.2.2026 13:00:00 CET | Press release

TarSeer™ BRETSA™ Target Engagement System enables studies for difficult proteins early in drug discovery Promega Corporation is launching a new live-cell target engagement platform that could close a long-standing gap between biochemical and cellular assays for understudied or difficult-to-interrogate proteins. The TarSeer™ BRETSA™ Target Engagement System is a novel bioluminescence resonance energy transfer-based shift assay for detecting ligand-protein interactions in intact cells using protein denaturation. It gives drug discovery researchers early, target-specific cellular insights by validating weak or early chemical matter and expanding the targets accessible in live-cell drug discovery workflows. The technology will be debuted at the Society for Laboratory Automation and Screening (SLAS) International Conference and Exhibition in Boston, February 7-11, 2026. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260206015371/

Eurofins Viracor BioPharma Expands Bioanalytical Capabilities9.2.2026 13:00:00 CET | Press release

Eurofins Viracor BioPharma Services, a long‑standing and trusted partner for clinical trial testing solutions with deep expertise in specialty biomarkers and molecular assays, announces a significant expansion of its service portfolio with the addition of enhanced bioanalytical testing capabilities. These new services are fully aligned with Good Laboratory Practices (GLP) and Good Clinical Practices (GCP), enabling the company to enhance support of biopharmaceutical development programs with greater scientific breadth throughout the drug development workflow. This strategic advancement follows the successful relocation and integration of Eurofins Pharma Bioanalytics Services from St. Charles, Missouri, into Eurofins Viracor BioPharma’s purpose‑built, eleven‑acre facility in Lenexa, Kansas. The bioanalytical organization brings more than two decades of specialized experience in pharmacokinetics, immunogenicity, and biomarker testing. By combining both laboratories’ strengths, Eurofins V

HKTDC to Host World’s Largest One-Stop Jewellery Marketplace9.2.2026 11:37:00 CET | Press release

New Hard Pure Gold Pavilion showcases breakthrough gold technologies Organised by the Hong Kong Trade Development Council (HKTDC), the world’s largest one‑stop jewellery marketplace will return in early March under its proven “Two Shows, Two Venues” format. The 12th Hong Kong International Diamond, Gem & Pearl Show will take place from 2 to 6 March at AsiaWorld‑Expo, featuring a wide range of jewellery raw materials. Also, the 42nd Hong Kong International Jewellery Show will be held from 4 to 8 March at the Hong Kong Convention and Exhibition Centre, showcasing finished jewellery pieces. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260207153040/en/ Hong Kong International Jewellery Show and Hong Kong International Diamond, Gem & Pearl Show Jenny Koo, Deputy Executive Director of the HKTDC, said: “This year’s twin jewellery shows bring together some 4,000 exhibitors from over 40 countries and regions, with nearly 70% coming

FlexTrade Integrates CME Group’s FX Spot+ and EBS Market Offerings for Enhanced FX Trading9.2.2026 11:30:00 CET | Press release

The initiative will see FlexTrade FX clients seamlessly access CME Group’s primary FX markets within FlexFX. FlexTrade Systems(@FlexTrade), a global leader in multi-asset execution and order management systems, today announced an integration with CME Group’s EBS Market central limit order book (CLOB) and its FX Spot+ platform.The move is designed to diversify and deepen the sources of actionable liquidity available to FlexTrade’s FlexFX users through an integration into CME Group's substantial liquidity pools for spots via FX Spot+. Providing firm, anonymous liquidity and no last-look pricing, EBS Market is a venue for both large market participants in search of FX liquidity in an all-to-all CLOB, and for market-making banks hedging FX risk. FX Spot+ further enhances spot liquidity with Futures liquidity from CME Group. This partnership is integral in helping firms further expand FX liquidity and take advantage of global opportunity. Mutual clients of FlexTrade and CME Group can integr

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye